By sharing this link, I acknowledge that I have read and understand the Terms and Conditions.
RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY
Nilotinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Tasigna (Nilotinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Tasigna is marketed by Novartis.
Model release not required. Property release not required.
Contact us if you require the original or other formats.